Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all patients succumb to acquired EGFR tyrosine kinase inhibitor resistance that occurs via diverse mechanisms. Th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Nat Commun
Autori principali: Jacobsen, Kirstine, Bertran-Alamillo, Jordi, Molina, Miguel Angel, Teixidó, Cristina, Karachaliou, Niki, Pedersen, Martin Haar, Castellví, Josep, Garzón, Mónica, Codony-Servat, Carles, Codony-Servat, Jordi, Giménez-Capitán, Ana, Drozdowskyj, Ana, Viteri, Santiago, Larsen, Martin R., Lassen, Ulrik, Felip, Enriqueta, Bivona, Trever G., Ditzel, Henrik J., Rosell, Rafael
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5583255/
https://ncbi.nlm.nih.gov/pubmed/28871105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-017-00450-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi